IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Serebruany, Victor L.	
Application No.:	10/811563	Group Art Unit: 1614
Filed:	March 29, 2004	Examiner: Not yet assigned
Confirmation No.:	1385	
Title:	Treating Vascular Events With Statins by Inhibiting PAR-1 and PAR-4	



CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

9/29/04 Antoinette Giugliano
Date Signature

Antoinette Giugliano
Typed or printed name of person signing certificate

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

[ ] under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

[X] under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

[ ] under 37 CFR 1.97(c) together with either:

[ ] a Statement under 37 CFR 1.97(e), as checked below, or

[ ] a $180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

[ ] under 37 CFR 1.97(d) together with:

[ ] a Statement under 37 CFR 1.97(e), as checked below, and

[ ] a $180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

[ ] under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

[ ] Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

[ ] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)
Applies to original applications (other than design) filed on or after May 29, 2000

[ ] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

[X] Enclosed herewith is form PTO-1449:

[X] Copies of the cited references are enclosed.

[X] Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.

[ ] Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]

[ ] The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

[ ] The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:

[ ] the explanation provided on the attached sheet.

[ ] the explanation provided in the Specification.

[ ] submission of the enclosed International Search Report.

[ ] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.

[ ] the enclosed English language abstract.

[ ] Applicant requests that the following non-published pending applications be considered:

Examiner's Initials

_____ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

_____ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

_____ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

_____ _____

Examiner Date

[ ] A copy of each above-cited application, including the current claims, is enclosed.

[ ] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[ ] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[ ] Please charge Deposit Account 08-0380 in the amount of $[ ]. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

ANTOINETTE G. GIUGLIANO, P.C.

By Antoinette G. Giugliano

Antoinette G. Giugliano
Registration No.: 42,582
Telephone: (781) 595-3737
Facsimile: (781) 593-7907

Lynnfield, MA 01940

Date: 9/29/04

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0004.0001-000	APPLICATION NO. 10/811,563	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Serebruany, Victor L.	FILING DATE March 29, 2004	
August 13, 2004 (Use several sheets if necessary)	EXAMINER Not Yet Assigned	CONFIRMATION NO. 1385	GROUP 1614

U.S. PATENT DOCUMENTS				
EXAM-INER INI-TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA			
	AB			

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	NO
	AL					
	AM					

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
	AR	Serebruany VL, *et al.,* Absence of Interaction Between Atorvastatin and Clopidogrel in Prospective Data: The Interaction of Atorvastatin and Clopidogrel (INTERACTION Study). *European Heart Journal*; vol 24 Suppl: 404 (March 31, 2003).
	AS	Serebruany, Victor L., *et al., Thrombosis Res.* 113(3-4): 197-204 (2004).
	AT	Saw, J. *et al.,* Lack of Adverse clopidogrel-atorvastatin Clinical Interaction..., *Circulation* 108(8):921-4 (2003).
	AU	Serebruany, Victor L. *et al.,* Effects of Clopidogrel and aspirin combination..., *Am Heart J.* 146(4) 713-20 (2003).
	AV	Serebruany, Victor L. *et al., Circulation,* 107(12):1568-1569 (April 1, 2003).
	AW	Hebert, PR *et al.* Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. *JAMA*. 278: 1660-1661 (1997).
	AX	Serruys, PW *et al.* Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. *JAMA*. 287: 3215-3222 (2002).

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0004.0001-000	APPLICATION NO. 10/811,563	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Serebruany, Victor L.	FILING DATE March 29, 2004	
August 13, 2004 (Use several sheets if necessary)	EXAMINER Not Yet Assigned	CONFIRMATION NO. 1385	GROUP 1614

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
	AY	Sotiriou CG, Cheng JW. Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol. *Ann Pharmacother.* 34:1432-1439 (2000).
	AZ	Takemolot, Masao *et al.,* Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. *Arterioscler Thromb Vasc Biol.*; 21:1712-1719 (2001).
	AR2	Sanguigni V. *et al.,* Increased superoxide anion production by platelets in hypercholesterolemic patients. *Thromb Haemost.* 87:796-801 (2002).
	AS2	Vu T-K.H., *et al.* Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. *Cell.* 64: 1057-1068 (1991).
	AT2	Kahn ML, *et al.* Protease activated receptors 1 and 4 mediate activation of human platelets by thrombin. *Clin Invest.* 103: 879-887 (1999).
	AU2	Brass LF, *et al.* Changes in the structure and function of the human thrombin receptor during receptor activation, internalization, and recycling. *J Biol Chem.* 269: 2934-2952 (1994).
	AV2	Puccetti L, *et al.* Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects. *Nutr Metab Cardiovasc Dis.* 11: 378-387 (2001).
	AW2	Savi P, *et al.* Identification and biological activity of the active metabolite of clopidogrel. *Thromb Haemost.* 84:891-896 (2000).
	AX2	Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. *Clin Pharmacokinet.* 41:343-370 (2002).
	AY2	Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. *Drug Metabol Dispos.* 31: 53-59 (2002).
	AZ2	Chambers RC, *et al.,* Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. *J Biol Chem.* Nov 10;275(45):35584-91 (2000).
	AR3	Phillips DR. Thrombin interaction with human platelets: potentiation of thrombin-induced aggregation and release by inactivated thrombin. *Thromb Diathesis Haemorrhag.* 32:207-215 (1974).

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	0004.0001-000	10/811,563	
August 13, 2004	FIRST NAMED INVENTOR Serebruany, Victor L.	FILING DATE March 29, 2004	
(Use several sheets if necessary)	EXAMINER Not Yet Assigned	CONFIRMATION NO. 1385	GROUP 1614

	AS3	Pilcher BK, Thrombin stimulates fibroblast-mediated collagen lattice contraction by its proteolytically activated receptor. *Exp Cell Res.* 211:368-373 (1994).
	AT3	Sower LE, Froelich CJ, Carney DH, Fenton JW II, Klimpel GR. Thrombin induces IL-6 production in fibroblasts and epithelial cells: evidence for the involvement of the seven-transmembrane domain (STD) receptor for -thrombin. *J Immunol.* 155:895-901 (1995).
	AU3	Rabiet M, Plantier J, Rival Y, Genoux Y, Lampugnani M, Del Mar EG. Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. *Arterioscler Thromb Vasc Biol.* 16:488-496 (1996).
	AV3	Kinlough-Rathbone RL, Rand ML, Packham MA. Rabbit and rat platelets do not respond to thrombin receptor peptides that activate human platelets. *Blood.* 82:103-106 (1993).
	AW3	Henriksen RA, Samokhin GP, Tracy PB. Thrombin-induced thromboxane synthesis by human platelets. Properties of anion binding exosite I-independent receptor. *Arterioscler Thromb Vasc Biol.* 17(12): 3519-26 (1997).
	AX3	Weksler, B. B., C. W. Ley, and E. A. Jaffe. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A23187. *J. Clin. Invest.* 62: 923-930 (1978).
	AY3	Sugama, Y., C. Tiruppathi, K. Janakidevi, T. T. Andersen, J. W. Fenton II, and A. B. Malik. Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: a mechanism for stabilizing neutrophil adhesion. *J. Cell Biol.* 119: 935-944 (1992).
	AZ3	Tannous, M. *et al.* Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. *Thromb Haemost.* 82:1390-1394 (1999).
	AR4	Puccetti, L. *et al.* Time-dependent effect of statins on platelet function in hypercholesterolaemia. *Eur J Clin Invest.* 32: 901-908 (2002).
	AS4	De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. *J Biol Chem.* 276(7):4692-8 (2001).
	AT4	Kahn, M. L. , Diacovo, T. G. , Bainton, D. F. , Lanza, F. , Trejo, J. & Coughlin, S. R. *Blood* 94, 4112-4121 (1999).

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	0004.0001-000	10/811,563	
August 13, 2004	FIRST NAMED INVENTOR Serebruany, Victor L.	FILING DATE March 29, 2004	
(Use several sheets if necessary)	EXAMINER Not Yet Assigned	CONFIRMATION NO. 1385	GROUP 1614

	AU4	Ramakrishnan, V. , Reeves, P. S. , DeGuzman, F. , Deshpande, U. , Ministri-Madrid, K. , DuBridge, R. B. & Phillips, D. R. *Proc. Natl. Acad. Sci. USA* 96, 13336-13341 (1999).
	AV4	Ramakrishnan, V. , DeGuzman, F. , Bao, M. , Hall, S. W. , Leung, L. L. & Phillips, D. R. *Proc. Nat. Acad. Sci. USA* 98, 1823-1828 (2001),
	AW4	Roth GJ, "A new "kid" on the platelet thrombin receptor "block": glycoprotein Ib-IX-V" *Proc Natl Acad Sci U S A* 98(4):1330-1 (2001).
	AX4	Neubauer, Horst, *et al., European Heart J.* 24(19):1744 (October 2003).
	AY4	Saucedo, Jorge F., *et al., Circulation* 108 (17 supplement):IV-579 (October 28, 2003).
	AZ4	Muller, Iris, *et al., Circulation* 108(18):2195-2197 (November 4, 2003).
	AR5	Olvotti, L., *et al.* High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes. *Blood Coag Fibrin.* 13:315-322 (2002).
	AS5	Gaddam, V., *et al., J. Cardiovascular Pharm & Therap*, 7(4):247-253 (October 2002).
	AT5	Puccetti, L. *et al., European J. of Clinical Investig.*, 32(12):901-908 (December 2002).
	AU5	Laufs, U *et al.*, Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. *Stroke* 10:2442-2449 (2000).
	AV5	Law, Wei C.., *et al., Circulation,* 102(18 supplement):II.429 (October 31, 2000).
	AW5	Lau, WC, *et al.,Circulation,* 107(1):32-37 (2003).

EXAMINER	DATE CONSIDERED